Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-02-28

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if the oral supplementation with curcumin reduces proteinuria in patients with chronic kidney disease regardless the ethiology.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Curcumin in Patients in Chronic Kidney Disease

NCT03475017

Chronic Kidney Diseases

COMPLETED NA

Curcumin and Exercise in Chronic Kidney Disease

NCT04132648

Chronic Kidney Diseases Blood Pressure Hyperemia +1 more

WITHDRAWN PHASE2

Curcumin and Vascular and Cognitive Function in Patients With Chronic Kidney Disease

NCT03223883

Chronic Kidney Diseases Cognitive Decline

COMPLETED PHASE2

Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD

NCT02494141

Polycystic Kidney, Autosomal Dominant

COMPLETED PHASE4

Role of Turmeric on Oxidative Modulation in ESRD Patients

NCT01906840

End Stage Renal Failure

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Curcumin is a potent antioxidant found in extracts of the rhizome of the plant Curcuma longa L.

Different studies have demonstrated that curcumin has potent biological activity and therefore is an effective therapeutic agent for the treatment of various ailments.

This compound acts as a bifunctional antioxidant:

ه is capable of reacting directly with highly reactive oxygen species. ه acts indirectly by its ability to induce the expression of various cytoprotective proteins through Keap1/Nrf2/ARE pathway.

Although RAAS blockade is the cornerstone to prevent the progression of proteinuric nephropathy, a significant number of patients remained with proteinuria and progress to end-stage renal disease.

Due to the low cost and few side effects of curcumin, this could become an adjuvant treatment of proteinuric nephropathy purposes attenuate the progression of chronic kidney disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Proteinuria

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diabetic

Group Type ACTIVE_COMPARATOR

Curcumin

Intervention Type DRUG

Non-diabetic

Group Type ACTIVE_COMPARATOR

Curcumin

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Curcumin

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Turmeric

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of proteinuric chronic kidney disease with 1g or more of proteins in a daily recollection.
* Individuals taking Angiotensin II Receptor Blocker or ACE inhibitors in monotherapy with maximum dose or in combination.

Exclusion Criteria

* Hepatic damage.
* Malignancy.
* Pregnancy.
* Peritoneal or hemodialysis.
* Organ transplantation.
* Heart failure classification III or IV (New York Heart Association).
* History of chemotherapy within 2 years prior to screening.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No